We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
GSK plc | NYSE:GSK | NYSE | Depository Receipt |
Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-1.02 | -2.23% | 44.76 | 45.77 | 44.94 | 45.77 | 4,981,276 | 01:00:00 |
By Ian Walker
Sanofi S.A. and GlaxoSmithKline PLC said Wednesday that they have reached an agreement with the U.K. government to supply up to 60 million doses of a Covid-19 vaccine, subject to final contract.
The French and U.K. pharmaceutical companies said the vaccine candidate is based on Sanofi's technology that produces an influenza vaccine as well as GSK's pandemic adjuvant technology.
Sanofi is leading clinical development and registration of the Covid-19 vaccine and plans a Phase 1, 2 study in September, followed by a Phase 3 study by the end of the year. If data proves positive, regulatory approval could be received in the first half of next year, it said.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
July 29, 2020 01:39 ET (05:39 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions